TetraGenetics continually seeks partners to leverage our TetraExpress™ technology and our unique ion channel antibody discovery capabilities. We are particularly interested in partnerships for the discovery and development of novel ion channel therapeutics, both biologics and small molecule, for autoimmune diseases and pain. TetraGenetics also partners in the development of therapeutics targeting other membrane proteins including G protein-coupled receptors. We welcome interest from pharmaceutical and biotechnology companies interested in sharing technology and know-how to discover, develop and bring to market novel therapeutics for human diseases.
For more information about licensing opportunities or partnering with TetraGenetics, please contact:
Yelena Bisharyan, Ph.D.
Director of External Alliances